CDKN2B and astrocytoma (excluding glioblastoma): An important refinement in WHO 2021 is the addition of homozygous deletion of CDKN2A and/or CDKN2B to the grading of IDH-mutant astrocytomas [2], related to the negative survival implications [19, 20].